方法对127例原发性小肝癌患者（SHCC）进行射频消融（RFA）及经皮瘤内无水酒精注射治疗（PEIT），其中RFA组81例共97个病灶，PEIT组46例共59个病灶。
基于76个网页-相关网页
PURPOSE:To analyze factors that affect percutaneous ethanol injection therapy (PEIT), in order to improve PEIT technology.
目的：分析肝癌患者瘤内无水乙醇注射治疗（PEIT）疗效的影响因素，完善治疗技术。
Chemoablation of the liver cancer include both percutaneous ethanol injection therapy (PEIT) and percutaneous acetic acid injection therapy (PAIT).
经皮化学灭活介入治疗肝癌主要有经皮无水乙醇瘤内注射(PEIT)和经皮乙酸注射(PAIT)两种。
Objective to observe the effects of percutaneous ethanol injection therapy (PEIT) for advanced liver metastases and to explore the dose of ethanol.
目的观察无水酒精瘤内注射治疗肝转移癌的疗效，并探讨无水酒精的用量。
应用推荐